Beam Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $26.09
- Today's High:
- $26.92
- Open Price:
- $26.25
- 52W Low:
- $28.04
- 52W High:
- $73.27
- Prev. Close:
- $26.1
- Volume:
- 839396
Company Statistics
- Market Cap.:
- $2.59 billion
- Book Value:
- 10.549
- Revenue TTM:
- $76.70 million
- Operating Margin TTM:
- -470.93%
- Gross Profit TTM:
- $-250674000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.21%
- Return on Equity TTM:
- -36.14%
Company Profile
Beam Therapeutics Inc had its IPO on 2020-02-06 under the ticker symbol BEAM.
The company operates in the Healthcare sector and Biotechnology industry. Beam Therapeutics Inc has a staff strength of 523 employees.
Stock update
Shares of Beam Therapeutics Inc opened at $26.25 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $26.09 - $26.92, and closed at $26.18.
This is a +0.31% increase from the previous day's closing price.
A total volume of 839,396 shares were traded at the close of the day’s session.
In the last one week, shares of Beam Therapeutics Inc have increased by +11.59%.
Beam Therapeutics Inc's Key Ratios
Beam Therapeutics Inc has a market cap of $2.59 billion, indicating a price to book ratio of 4.4265 and a price to sales ratio of 32.425.
In the last 12-months Beam Therapeutics Inc’s revenue was $76.70 million with a gross profit of $-250674000 and an EBITDA of $-345700000. The EBITDA ratio measures Beam Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Beam Therapeutics Inc’s operating margin was -470.93% while its return on assets stood at -16.21% with a return of equity of -36.14%.
In Q1, Beam Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 187.1%.
Beam Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Beam Therapeutics Inc’s profitability.
Beam Therapeutics Inc stock is trading at a EV to sales ratio of 24.3931 and a EV to EBITDA ratio of -7.4731. Its price to sales ratio in the trailing 12-months stood at 32.425.
Beam Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.33 billion
- Total Liabilities
- $219.93 million
- Operating Cash Flow
- $25.45 million
- Capital Expenditure
- $6.02 million
- Dividend Payout Ratio
- 0%
Beam Therapeutics Inc ended 2024 with $1.33 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.33 billion while shareholder equity stood at $761.51 million.
Beam Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $219.93 million in other current liabilities, 744000.00 in common stock, $-1153822000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $249.77 million and cash and short-term investments were $1.06 billion. The company’s total short-term debt was $11,157,000 while long-term debt stood at $0.
Beam Therapeutics Inc’s total current assets stands at $1.08 billion while long-term investments were $0 and short-term investments were $809.70 million. Its net receivables were $0 compared to accounts payable of $14.06 million and inventory worth $0.
In 2024, Beam Therapeutics Inc's operating cash flow was $25.45 million while its capital expenditure stood at $6.02 million.
Comparatively, Beam Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $26.18
- 52-Week High
- $73.27
- 52-Week Low
- $28.04
- Analyst Target Price
- $67
Beam Therapeutics Inc stock is currently trading at $26.18 per share. It touched a 52-week high of $73.27 and a 52-week low of $73.27. Analysts tracking the stock have a 12-month average target price of $67.
Its 50-day moving average was $27.44 and 200-day moving average was $34.72 The short ratio stood at 15.29 indicating a short percent outstanding of 0%.
Around 190.4% of the company’s stock are held by insiders while 8543.9% are held by institutions.
Frequently Asked Questions About Beam Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.